Lenz Therapeutics, Inc. <LENZ.O>: Citigroup cuts target price to $10 from $20
LENZ•Related News
Unicycive Therapeutics Announces Second Quarter 2026 Financial Results And Provides Business Update
UNCY•
Teck secures bondholder consents for indenture amendments, pays consent fee of U.S. $1 per U.S. $1,000 principal amount
TECK•
Protalix publishes corporate presentation highlighting Elfabrio commercialization and PRX-115 Phase 2 gout study
PLX•
Adagene FY26 H1 net loss widens to US$ 16.4 million; revenue turns to US$ 1.6 million
ADAG•
Lumentum Holdings Inc <LITE.O>: Morgan Stanley Raises Target Price to $1000.00 From $900.00
LITE•